Abbott Spins off Biopharm Operations into AbbVie
Abbott Laboratories spun off its branded biopharmaceutical operations into AbbVie, an $18 billion-a-year business focused on building a broad portfolio anchored by Abbotts top-selling drug, the anti-TNF biologic Humira.